These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18028489)

  • 41. Rebound pustular psoriasis after brodalumab discontinuation.
    Khemis A; Cavalié M; Montaudié H; Lacour JP; Passeron T
    Br J Dermatol; 2016 Nov; 175(5):1065-1066. PubMed ID: 27037661
    [No Abstract]   [Full Text] [Related]  

  • 42. Psoriasis-associated aseptic pneumonitis: another cause of lung involvement in psoriasis.
    Suárez-Amor O; Monteagudo B; Cabanillas M; Ramírez-Santos A
    Australas J Dermatol; 2014 Nov; 55(4):306. PubMed ID: 25399794
    [No Abstract]   [Full Text] [Related]  

  • 43. Severe myalgia associated with brodalumab treatment in a patient with psoriasis.
    Ichiyama S; Matano Y; Hoashi T; Kanda N; Nagayama H; Saeki H
    J Dermatol; 2018 Dec; 45(12):e327-e328. PubMed ID: 29782052
    [No Abstract]   [Full Text] [Related]  

  • 44. Successful treatment of PD-1 inhibitor-induced psoriasis with infliximab.
    Hansen I; Heidrich I; Abeck F; Kött J; Booken N; Gebhardt C; Schneider SW
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e621-e623. PubMed ID: 36424911
    [No Abstract]   [Full Text] [Related]  

  • 45. Pityriasis lichenoides chronica induced by infliximab, with response to methotrexate.
    López-Ferrer A; Puig L; Moreno G; Camps-Fresneda A; Palou J; Alomar A
    Eur J Dermatol; 2010; 20(4):511-2. PubMed ID: 20395191
    [No Abstract]   [Full Text] [Related]  

  • 46. Multiple eruptive dermatofibromas in a patient receiving efalizumab.
    Santos-Juanes J; Coto-Segura P; Mallo S; Galache C; Soto J
    Dermatology; 2008; 216(4):363. PubMed ID: 18292655
    [No Abstract]   [Full Text] [Related]  

  • 47. Efalizumab-induced lupus-like syndrome.
    Durox H; Sparsa A; Loustaud-Ratti V; Prey S; Gondran G; Manea P; Vidal E; Bedane C
    Acta Derm Venereol; 2008; 88(3):270-1. PubMed ID: 18480928
    [No Abstract]   [Full Text] [Related]  

  • 48. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus.
    Reich K; Griffiths C; Barker J; Chimenti S; Daudén E; Giannetti A; Gniadecki R; Katsambas A; Langley R; Mrowietz U; Ogilvie A; Ortonne JP; Reider N; Saurat JH
    Dermatology; 2008; 217(3):268-75. PubMed ID: 18685261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Migraine with aura induced by efalizumab.
    Kluger N; Heroum C; Michot C; Guillot B; Bessis D
    Clin Exp Dermatol; 2009 Oct; 34(7):e401-2. PubMed ID: 19549238
    [No Abstract]   [Full Text] [Related]  

  • 50. Septic shock after treatment of pyoderma gangrenosum with infliximab.
    Wölbing F; Fierlbeck G; Hötzenecker W; Schaller M; Röcken M
    Acta Derm Venereol; 2009; 89(1):93-4. PubMed ID: 19197554
    [No Abstract]   [Full Text] [Related]  

  • 51. Immune thrombocytopenia associated with efalizumab therapy for psoriasis.
    Warkentin TE; Kwon P
    Ann Intern Med; 2005 Nov; 143(10):761-3. PubMed ID: 16287807
    [No Abstract]   [Full Text] [Related]  

  • 52. Anti IL-17 flared psoriasis in a patient on secukinumab.
    Noell C; McQuade B; Gottlieb A; Rosmarin D
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28547879
    [No Abstract]   [Full Text] [Related]  

  • 53. Guselkumab (Tremfya) for psoriasis.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):179-180. PubMed ID: 29125591
    [No Abstract]   [Full Text] [Related]  

  • 54. Recurrent angioedema associated with efalizumab.
    Mallbris L; von Bergen F; van Hage M; Ståhle M
    Acta Derm Venereol; 2009 Nov; 89(6):665-6. PubMed ID: 19997712
    [No Abstract]   [Full Text] [Related]  

  • 55. Eczematous eruption in patients with psoriasis during risankizumab treatment.
    Kromer C; Schön MP; Mössner R
    Eur J Dermatol; 2020 Oct; 30(5):599-601. PubMed ID: 33185530
    [No Abstract]   [Full Text] [Related]  

  • 56. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
    Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
    Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. De novo onset of arthritis in patients previously treated with efalizumab: an observational case series.
    Colina M; Cianco G; Khodeir M; Sferra S; Scanavacca P; Corazza M; Virgili A; Trotta F
    Clin Exp Rheumatol; 2011; 29(1):141. PubMed ID: 21345301
    [No Abstract]   [Full Text] [Related]  

  • 58. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
    Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
    J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis.
    Quach OL; Hsu S
    JAMA Dermatol; 2016 Apr; 152(4):486-7. PubMed ID: 26720159
    [No Abstract]   [Full Text] [Related]  

  • 60. Peripheral neuropathy in two patients with psoriasis in treatment with infliximab.
    Eguren C; Díaz Ley B; Daudén E; García-Diez A; Losada M
    Muscle Nerve; 2009 Sep; 40(3):488-9. PubMed ID: 19623630
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.